Aspire Biopharma Holdings, Inc.
ASBPNASDAQHealthcareBiotechnology

About Aspire Biopharma Holdings

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

Company Information

CEOKraig Higginson
Founded2021
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone415 592 7399
Address
23150 Fashion Drive, Suite 232 Estero, Florida 33928 United States

Corporate Identifiers

CIK0001847345
CUSIP738920107
ISINUS7389201077
SIC2834

Leadership Team & Key Executives

Kraig T. Higginson
Interim Chief Executive Officer, President and Executive Chairman of the Board
Ernest J. Scheidemann Jr.
Chief Financial Officer
Stephen E. Quesenberry
General Counsel and Corporate Secretary